<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551172</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROMA-301</org_study_id>
    <nct_id>NCT02551172</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD</brief_title>
  <official_title>An Efficacy and Safety Study of HCP1105 Capsule in Combined Hyperlipidemic Patients With High Risk for Coronary Heart Disease (CHD): A Randomized,Double-blind, Multicenter, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety after administration of HCP1105 in hyperlipidemic
      patients with high risk for CHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An efficacy and safety study of HCP1105 Capsule in combined hyperlipidemic patients with high
      risk for Coronary Heart Disease(CHD): A randomized,double-blind, multicenter, phase 3 study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean rate of change of non-HDL-C (%) from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of HDL-C (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of LDL-C (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of Triglyceride (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of Total cholesterol (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of Total apo A1 (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of Total apo B (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of Lipoprotein(a) (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of change of hs-CRP (%) from baseline</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the subjects who meet the target level of treatment</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
    <description>target level (Non-HDL-C&lt;130mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>experimental sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparative sequence</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1105</intervention_name>
    <description>Rosuvastatin + Omega-3-acids ethyl esters</description>
    <arm_group_label>experimental sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0816</intervention_name>
    <description>Rosuvastatin</description>
    <arm_group_label>experimental sequence</arm_group_label>
    <arm_group_label>comparative sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of HCP1105</intervention_name>
    <description>Soybean Oil</description>
    <arm_group_label>comparative sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of HGP0816</intervention_name>
    <description>Exclusion of Rosuvastatin in HGP0816</description>
    <arm_group_label>experimental sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 19≤

          -  Subjects who have ability to comprehend the objectives, contents of study and property
             of study drug before participating in trial and have willingness to sign of informed
             consent in writing

        Exclusion Criteria:

          -  History of clinically significant hypersensitivity reaction with HMG-CoA reductase
             inhibitor and Omega-3

          -  Subject who has active liver disease and severe liver failure(Continuous elevation of
             AST,ALT level with unspecified cause or AST, ALT level exceeds more than three times
             of maximum upper range.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-yeol Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medecal Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Hee Jung</last_name>
    <phone>02-3010-3246</phone>
    <email>chjung0204@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Euljii General Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Young Jang</last_name>
      <phone>+82-2-970-8216</phone>
      <email>erica_37@naver.com</email>
    </contact>
    <investigator>
      <last_name>Kyung Ah Han, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>September 15, 2015</last_update_submitted>
  <last_update_submitted_qc>September 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

